Intelligence

Home / Intelligence

Type
  • All
  • Blog
  • Briefs
  • Case Studies
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Featured Topic
  • All
  • AIML
  • Analytics
  • APAC
  • Benchmarking
  • Biosimilars
  • CAR-T
  • Cell and Gene Therapy
  • Commercial Operations
  • Competitive Intelligence
  • Contract Analytics
  • Corporate Strategy
  • COVID-19
  • Data Management
  • Digital Therapeutics
  • Diversity
  • Emerging Life Sciences
  • Europe
  • Evidence Strategy (HEOR)
  • Field Force
  • Forecasting
  • Generative AI
  • Incentive Compensation
  • Inflation Reduction Act
  • Insights
  • International
  • LatAm
  • Launch and Brand Excellence
  • Learning and Development
  • Market Research
  • Marketing
  • MedTech
  • New Product Planning
  • NRDL
  • Omnichannel
  • Oncology
  • Patient Centricity
  • Patient Finding
  • Patient Services
  • Performance Tracking
  • Pricing and Access
  • Product Demos
  • Rare Disease
  • Real-World Evidence
  • Scientific Publications
  • Talent Acquisition and Retention
  • United States
  • Value Communication
Search
Brain, thoughts

Webinars

Behavioral Science & Concept Testing Research: Getting Deeper Responses than “I Hate the Color Blue”

June 25, 2024 | 1:00 - 1:45 PM ET

High-impact, optimized marketing communication materials are vital, no matter where a brand is in the product lifecycle. Join Lisa Bailey as she hosts a wide-ranging discussion on tips and tricks from the field with presenters Monique Marsh, Kristen Tierhold and Sabrina Jordan.

Sign Up Now

Blog

Global Evidence Requirements to Launch a Digital Health Technology

Published November 12, 2021

Executive Summary Given the growing number of digital health technologies available, there is a wide range of frameworks that outline key requirements to support decision-makers with the value assessment of digital health solutions Understanding how requirements differ based on the country and organization that develops the framework is key to prepare the successful global launch of a digital health technology Clinical evidence that demonstrates an improvement in the state of health or quality of life should be taken into consideration…

Read Now

Blog

Are Current Reimbursement Options for Opioid Use Disorder DTx Causing a Barrier to Widespread Adoption in the USA?

Published November 9, 2021

In 2020, Trinity assessed three applications developed to treat Opioid Use Disorders (OUD) (e.g., reSET-O, Connections, DynamiCare) through the lens of ICER conducting a cost-effectiveness evaluation. Only a year later, several more health tech startups have adopted a preventative outlook and seek to address chronic pain with digital health tools (e.g., phone applications). A key focal point is the current public health issue faced by the US with ~2.1 million Americans diagnosed with OUD. These applications, including Clearing, Curable, Remedee Labs, Swing Therapeutics…

Read Now

Webinars

Imperatives for Optimizing Your Commercial Data Environment

Available On Demand

Whether you are preparing to deploy your commercial data environment or considering changes to your existing infrastructure, don’t be left wondering. There is a lot to consider from both a strategy and day-to-day operational perspective to ensure you are making optimal decisions.Trinity Life Sciences invites you to join us for a webinar created specifically for emerging and pre-commercial life sciences companies. After working with many companies in your shoes, we have compiled the most important “Did You Knows.” Come learn…

Watch Now

Blog

Insulin Approval Pathways USA vs. EU

Published November 2, 2021

Executive Summary In March 2020, the FDA amended its classification of add-on insulin products, changing the approval pathway from that of a chemical drug follow-on to a biosimilar and more closely aligning with the EMA’s longstanding biosimilar insulin approval pathway The FDA approved the Semglee Pen (insulin glargine) as the first product through the new biosimilar insulin approval pathway in July 2021; the Semglee was priced as almost three times less costly in the USA than the previously approved biosimilar…

Read Now

Blog

Cell and Gene Therapy Landscape: Challenges and Opportunities for Biotech and Investors

Published October 19, 2021

Executive Summary The American Society of Cell & Gene Therapy (ASCGT) wrapped up their 2021 conference earlier this year, which covered a range of topics, from new scientific advances to the evolving pricing and market access dynamics surrounding cell and gene therapies (CGT). Trinity had the opportunity to attend the conference, which brought together stakeholders from across the CGT landscape to discuss some of the challenges and opportunities within the space today. In this post we will cover the most…

Read Now

Webinars

MedTech in the Post-COVID World: Where Do We Go From Here?

Available On Demand

October 28, 2021 | 1:00-1:45 pm ET Trinity MedTech, a part of Trinity Life Sciences, invites you to our webinar, MedTech in the Post-COVID World: Where Do We Go From Here? We will share data from our real-world evidence team on key sectors within the broader MedTech industry to show the impact of COVID on different MedTech lines of business. We will also explore what the implications are moving forward for companies/brands. In particular, what are best practice companies/brands doing…

Watch Now

White Papers

Navigating the New World of Virtual Conferences

The Example of ASCO 2021 While people were expecting to return to in-person conferences soon, the emergence of the Delta variant and the possibility of future unknown variants, combined with uneven vaccination rates, has created significant uncertainty about how soon that can happen. Trinity Life Sciences wanted to understand what perceptions medical conference attendees had of the new virtual conference world, what advantages and disadvantages they saw in it, and how manufacturers performed at engaging their audiences. We performed a…

Read Now

Blog

Assessing the Value of Non-Curative Cell and Gene Therapies

Published October 6, 2021

Executive Summary Given the majority of cell and gene therapies to date have offered the potential of a cure, pricing and access considerations are likely to differ for non-curative agents that are entering this space Although non-curative cell and gene therapies have demonstrated clinical efficacy (e.g., for multiple myeloma and wet age-related macular degeneration), manufacturers will need to communicate additional value offerings of these therapies to payers in order to avoid pushback and enhance access potential, such as: Robust evidence…

Read Now

Webinars

Brand Health 2022: A Strategic, Data-Driven Approach to Brand Assessment

Available On Demand

December 1st, 2021 | 1:00 pm EST In today’s highly competitive market, innovation and creativity are critical to create a strong Brand Strategy that supports meaningful differentiation.  A key challenge for life sciences companies in 2022 will be to identify the clearest strategies to address brand performance and assessing brand health for their unique context. Whether your brand is on-market already or is preparing for launch, leveraging a nuanced, evidence-based view of performance drivers – from prescriber adoption, to payer…

Watch Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.